Tongkat Ali

QUICK REF

• Evidence: 3/5 hypogonadal testosterone + stress/cortisol + ED + menopausal QoL; 2/5 sleep, fertility, strength; 1/5 cognition, muscle mass, longevity
• Dose: 100–400 mg/day standardized water extract (Physta 0.8–1.5 % eurycomanone, or LJ100 22 % eurypeptides / 40 % glycosaponins). Women: 50–100 mg/day
• Timing: Morning, with fat-containing meal; do NOT dose after 2 PM (insomnia is the top community-reported side effect)
• Lab/Monitor: AM total + free testosterone, SHBG, E2, LFTs at baseline → 8–12 wk → 6 mo; PSA if >40 y/o; hematocrit long-term
• Key interactions: Propranolol (absorption −29 %, PMID 21054461), anticoagulants (theoretical), immunosuppressants (theoretical enhancement), tadalafil/sildenafil (adulteration risk, not pharmacology)
• STATUS: CONDITIONAL — worth an 8–12 wk trial of Physta/LJ100 at 200 mg/day IF (a) documented hypogonadism total T < 12 nmol/L (345 ng/dL) on 2 morning draws OR (b) chronic psychological stress PSS > 20 OR (c) perimenopausal symptoms MENQOL-validated, AND (d) no active hormone-sensitive cancer, severe liver disease, pregnancy/lactation, or product from an uncertified Indonesian source. Evidence has plateaued since 2022 — Huberman-driven hype exceeds what the literature supports.

Clinical Summary

Tongkat Ali is a Southeast Asian herbal extract marketed as a natural testosterone booster. The clinical reality is narrower and weaker than the marketing: a modest, somewhat-replicated signal for raising testosterone in men already below the hypogonadal threshold, a small-RCT signal for lowering cortisol in chronically stressed adults, a borderline signal for erectile function, and one new 2025 signal for perimenopausal quality-of-life.

The evidence base has plateaued, not grown, since ~2022. Morgado's 2024 systematic review (PMID 37697053) of testosterone boosters classifies Tongkat Ali only as "possibly effective" — the second-weakest tier. No endocrine society guideline (Endocrine Society, AUA, ISSAM) mentions it. No Cochrane review exists. No Phase 3 RCT is registered globally; the only Phase 4 (NCT06100432) is an N=90 Indonesian male-infertility trial whose results are due 2025-Q4. Leisegang 2022 (PMID 36013514, 5 RCTs N=343, SMD 1.35) remains the cornerstone and is industry-adjacent (Malaysian Physta pipeline).

The mechanism is stimulatory rather than supplementary: quassinoids (primarily eurycomanone) modulate the HPG axis, raising LH/FSH and endogenous testosterone without suppressing feedback loops, and normalize HPA-axis cortisol without sedation. A 2025 mechanism paper adds dopaminergic stimulation in CNS cells (PMID 39066784) and a Japanese group linked the herb to AANAT/melatonin biosynthesis (PMID 40395793) — biologically plausible but not clinically translated.

The key safety signal most users do not know about: EFSA 2021 rejected Tongkat Ali as a novel food in the EU, citing positive in vitro chromosomal aberration assays and an in vivo comet assay at 2,000 mg/kg that induced DNA damage in stomach and duodenum first-contact tissues (PMID 34987621). Two published DILI case reports now exist (PMID 38646387; ACG 2025 abstract S5927), and LiverTox opened a dedicated entry in 2024 (NBK609015). These signals are weak (a handful of cases against enormous consumer exposure) but non-zero and underreported by commercial content.

The product-quality axis is more dangerous than the pharmacology. Ang 2004/2006 (PMID 15162849, PMID 16567029) found mercury above 0.5 ppm in 26–36 % of Malaysian Tongkat Ali products. The FDA has issued multiple warning letters for products adulterated with undeclared sildenafil or tadalafil (MS Bionic 2017, Synaptent 2021, HIS Enterprise / Adam's Secret 2023). Indonesian wild-harvest is the dominant current source, less regulated than Malaysian Physta. A reader who chooses a random Amazon "1000 mg 200:1 extract" is running a very different risk profile than a reader who buys Physta or LJ100 through a certified channel.

Bottom line: a low-risk, low-to-moderate-effect adjunct for narrow indications. Not hormonal therapy. Not a muscle-builder. Not a cognitive enhancer. Not a longevity compound.

Indications & Evidence

Legend — Type codes (Ataraxia Mode 5 causal taxonomy): DC = Direct Causal · PC = Probable Causal · UCC = Uncertain Causal · BC = Biomarker Correlation · SE = Surrogate Endpoint · ME = Mechanistic Extrapolation · AHE = Associative-Hypothesis Evidence (ceiling 2/5) · OA = Observational Association · RC = Reverse Causation · CF = Confounded · FA = False Association · NE = No Effect.

Bradford Hill (/9): strength, consistency, specificity, temporality, gradient, plausibility, coherence, experiment, analogy.

Safety flags: -- = no FAERS signal · MON = monitor (mild/manageable AEs) · WARN = serious signal · AVOID = contraindicated for this use.

Prescribing

Form & Standardization

Only two extracts carry the RCT evidence: Physta (Biotropics Malaysia; 0.8–1.5 % eurycomanone, ≥22 % eurypeptides, 40 % glycosaponins; Malaysian Standard MS2409) and LJ100 (HP Ingredients USA; self-affirmed GRAS; same standardization profile). Unstandardized root powder or generic "200:1 extract" products carry the bulk of adulteration and contamination reports — the adulteration risk is not theoretical (see Safety § Contamination).

Dose

• Male hypogonadism (documented): 200–400 mg/day Physta or LJ100, once daily with breakfast. Start 200 mg; titrate to 300–400 mg at week 4 if response inadequate.
• Stress reduction: 200 mg/day (Talbott dose). No evidence higher doses help for stress alone.
• Menopausal QoL (female): 100 mg/day Physta (Muniandy 2025 dose). 200 mg/day arm showed no additional benefit.
• Perimenopausal libido (female): 50–100 mg/day with careful self-monitoring; no safety data beyond MENQOL RCTs.
• Athletic strength (adjunct to training): 300 mg/day.
• Maximum practical daily dose: 400 mg/day. Beyond this, insomnia and palpitation reports climb without evidence of added benefit.

Timing & Food

• Take with breakfast containing 10–15 g fat (quassinoids are lipophilic; fat raises absorption ~30–40 %).
• Dose before 2 PM. Late dosing consolidates wakefulness via the same mechanism that raises alertness in the morning — this is the single most under-communicated side effect and aligns with Sakai 2024 mouse EEG data (PMID 39055967).
• Space 2–3 hours from PPIs, antacids, and high-calcium / high-iron supplements.

Cycling

No cycling required for efficacy; unlike exogenous androgens, Tongkat Ali does not suppress endogenous production. Optional 5-on / 2-off (Greenfield protocol) or 8-wk-on / 2-wk-off patterns are cost-saving conventions without RCT support. Continuous use up to 12 months is safe in RCTs; >12 months has no direct data.

Baseline & Monitoring

• Baseline (before starting): AM total + free testosterone (2 draws on separate mornings for documented hypogonadism), SHBG, estradiol, LH/FSH (to rule out secondary hypogonadism), PSA (men >40), ALT / AST, complete blood count (hematocrit).
• 8–12 weeks: repeat testosterone and LFTs. Decision point — if no response and no symptom change, discontinue.
• 6 months: PSA, LFTs, hematocrit; reassess goal.
• Stop criteria: LFTs >3× upper limit of normal, hematocrit >54 %, new-onset arrhythmia, PSA rise >0.75 ng/mL/year, persistent insomnia at morning dose, persistent irritability/aggression.

Condition-Specific Protocols (3/5 Indications)

Late-onset Hypogonadism (LOH / ADAM)

• Candidate: men ≥40, two AM total T draws <12 nmol/L (345 ng/dL), confirmed ADAM symptoms, no contraindications. Rule out pituitary/testicular pathology via LH, FSH, prolactin, ferritin.
• Protocol: Physta 200 mg/day with breakfast × 8 weeks → retest total + free T. If response ≥20 % or symptom improvement, continue to 12 weeks → reassess. If no response, escalate to 300–400 mg × 4 weeks then retest; if still no response, discontinue.
• Response rate: ~65–75 % of hypogonadal men respond with clinically meaningful increase (Leisegang 2022 SMD 1.35). Response is strongly baseline-dependent — men with T >15 nmol/L typically see <7 % change, which is indistinguishable from diurnal variation.
• Discontinuation: effects fade over 2–4 weeks after stopping. No rebound crash.

Chronic Psychological Stress

• Candidate: PSS score 14–24 (moderate chronic stress), not meeting criteria for clinical anxiety or depression.
• Protocol: 200 mg/day × 4 weeks → PSS reassess. Talbott 2013 showed cortisol −16 %, tension −11 %, anger −12 %, confusion −15 % at 4 weeks (N=63, small trial, not replicated at scale).
• Note: not a substitute for psychiatric care in clinical anxiety/depression/PTSD.

Mild-to-Moderate ED (with concurrent low-T signal)

• Candidate: IIEF-5 ≤21, especially with concurrent total T <12 nmol/L. Pure vascular ED is not an indication.
• Protocol: 200–300 mg/day × 12 weeks. Effect size small-to-moderate (Kotirum MA SMD 0.36, heterogeneity I²=89.5 % flags inconsistency). Can be stacked with PDE-5 inhibitors as-needed without interaction.

Perimenopausal / Postmenopausal QoL

• Candidate: women 40–55 with MENQOL-validated menopausal symptoms. No active breast/uterine/ovarian cancer; no pregnancy/lactation; no hormone-sensitive cancer history.
• Protocol: Physta 100 mg/day × 12 weeks (Muniandy 2025 dose). Primary benefit: overall MENQOL domain reduction ~34 % with hormonal neutrality (no change in E2, FSH, testosterone). Note: 200 mg arm did not outperform 100 mg.
• Caveat: only 2 RCTs exist, both sponsor-funded (Biotropics); primary endpoint p=0.049 is borderline. Use cautiously and reassess at 12 weeks.

Safety

Contraindications

Absolute: active prostate, breast, or other hormone-sensitive cancer; pregnancy; lactation; children/adolescents <18; severe hepatic impairment (Child-Pugh C).

Relative (require medical supervision): moderate BPH with obstructive symptoms; history of hormone-sensitive cancer in remission; Child-Pugh B hepatic impairment (reduce dose to 200 mg/d, monthly LFT × 3 mo); NYHA III heart failure; pre-existing arrhythmia (atrial flutter case reported, PMID 41080360); active autoimmune disease on immunosuppression (theoretical antagonism); renal impairment GFR <30 mL/min (limited data).

Adverse Effects (Clinical)

FAERS Signal Table

FAERS interpretation: 14 total reports across Eurycoma longifolia + Tongkat Ali strings, only 2 with the herb as suspect drug. The single serious cluster (Finland 2021, report 19087427) lists policosanol as primary suspect with additional metal poisoning and drug abuse coding — strongly suggestive of contaminated product plus polysupplement stack, not a clean Tongkat Ali hepatotoxicity signal. After noise subtraction, FAERS is effectively null for oral standardized Tongkat Ali. (Consistent with the general FAERS-is-noise-for-supplements pattern.)

Contamination & Adulteration (primary safety axis)

• Heavy metals (mercury): Ang 2004 (PMID 15162849) found 36 % of 100 Malaysian Tongkat Ali products exceeded 0.5 ppm mercury (range 0.52–5.30 ppm). Ang 2006 Tongkat Ali Hitam cohort: 26 % exceeded. Indonesian wild-harvest from Kalimantan is higher-risk than Malaysian Physta.
• PDE-5 adulteration: FDA warning letters — MS Bionic (Casanova Plus, 2017), Synaptent/Liftmode (2021, disease claims → unapproved drug), HIS Enterprise / Adam's Secret USA (2023, undeclared tadalafil + sildenafil). Some user "amazing results" reports on cheap Amazon products are explained by PDE-5 inhibitors present but undeclared.
• Identity/species adulteration: DNA-barcoding studies (PMID 30058427, PMID 30103564) found substantial substitution with non-Eurycoma species in commercial products.
• EU RASFF active notification 2025.7482: ongoing novel-food non-compliant imports flagged.
• Risk mitigation: buy Physta or LJ100 from suppliers with batch-specific CoAs showing eurycomanone %, heavy metals (Pb <5 ppm, As/Cd <0.5 ppm, Hg <0.2 ppm), microbial counts, and DNA-confirmed identity. Third-party certifications: USP Verified, NSF Certified for Sport, Informed Choice, ConsumerLab.

Genotoxicity Signal (EFSA 2021 — unique to this compound)

The EFSA Novel Food Panel (PMID 34987621, EFSA Journal 2021;19(12):6937) declined to approve Tongkat Ali water extract for food use at 200 mg/day, concluding: "the safety of the novel food has not been established under any condition of use." The basis was positive in vitro chromosomal aberration assays plus a positive in vivo alkaline comet assay at 2,000 mg/kg body weight localized to stomach and duodenum first-contact tissues (histopathology suggested genotoxicity, not cytotoxicity). This rejection is unknown to most US users and largely unmentioned in commercial content. It does not mean oral 200 mg/day is proven dangerous — the comet-positive dose is ~200× therapeutic exposure — but it is a red flag for long-term, high-dose, or mucosally-delivered use and for any user who prioritizes first-principles safety.

Drug Interactions

Synergies & Stacking

Antagonism / caution: high-dose antioxidants (may blunt training T response); anabolic steroids / TRT (redundant and may elevate E2 — Bodybuilding forum N=1 TRT+TA stack showed E2 +45 %, refuting the aromatase-inhibitor claim).

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

No clinical pharmacogenomic RCT exists for Tongkat Ali. The following are plausibility-based, not evidence-based.

Community & Anecdotal Evidence

Everything in this section is anecdotal / community-sourced — not clinical evidence. N-sizes reflect thread/post volume, not trial subjects. Presented because (a) it surfaces side-effect patterns that RCTs underreport and (b) a compound that's this culturally over-promoted deserves a reality check from its actual users.

Source Clusters & Sentiment

• Reddit (r/Nootropics, r/Supplements, r/Testosterone, r/Biohackers, r/PEDs, r/StackAdvice) — >1,000 threads 2022–2026. Dominant sentiment: mixed-positive with growing skepticism post-2024.
• Longecity forum — multi-page threads since ~2010. Mixed-positive; consensus "maintainer, not booster."
• Bodybuilding.com / EliteFitness / AnabolicMinds — older skeptical tradition; consensus "mildly positive but underwhelming vs prohormones/TRT."
• YouTube — Gray Matter Lifting 1-year N=1 (T 344→383 ng/dL, no increase; libido/morning-wood improved), More Plates More Dates (skeptical of Huberman endorsement), Pigmie (hair-shedding case).
• Examine.com community — measured, flags EFSA genotoxicity + DILI + heavy metals most accurately.
• East/Southeast Asian traditional — Indonesian Pasak Bumi jamu (root decoctions, multi-gram); Malaysian export-banned raw root (conservation status critically endangered); Vietnamese "Cay Ba Binh."

Most Commonly Reported Subjective Effects

Libido / morning wood (week 1–2) · erection quality · mood lift / reduced tension · motivation / assertiveness · "testicular fullness" (recurring specific report) · energy · focus / mild stimulant feel.

Most Commonly Reported Side Effects (Bold = under-communicated by commercial content)

1. Insomnia / restlessness if dosed after morning — the single most consistent under-reported AE. Matches Sakai 2024 mouse EEG data.
2. "Tongkat rage" / irritability / aggression — especially in young men with already-normal testosterone.
3. Heart palpitations at doses >400 mg or on adulterated products.
4. GI upset (5–10 %).
5. Headache.
6. Acne / oily skin (younger users).
7. Hair shedding — scientifically ambiguous; prominent YouTuber cases (Pigmie).
8. Testicular swelling — recurring specific report.

Folk Dosing vs Clinical Dosing

• Clinical reference: Physta / LJ100 100–400 mg/day, standardized.
• Typical Amazon product: 1,000 mg of "200:1 root extract" (Double Wood, Nutricost) — not equivalent to LJ100 standardization; eurycomanone content unknown.
• Traditional Pasak Bumi: multi-gram crude root decoction, centuries of use, different exposure profile entirely.
• Overshoot drives side effects. Insomnia, palpitations, and "tongkat rage" reports cluster at folk doses above the 400 mg clinical ceiling.

Reported Synergies (community consensus, no RCT support)

Ashwagandha (most popular, cortisol counterbalance) · Zinc/Vit D3/Magnesium (Huberman 5-supplement stack) · Fadogia Agrestis (Huberman) · Shilajit · Pine Pollen (Greenfield) · Cistanche / Tribulus (legacy bro-science, mostly debunked).

Red Flags & Skepticism Notes

1. Huberman / Momentous commercial conflict. Huberman's 2022 endorsement of the TA + Fadogia stack coincided with undisclosed Momentous Scientific Advisory Board membership and a multi-year commercial partnership. NY Magazine's 2024 "Mechanisms of Control" cover sparked broader scrutiny. Momentous quietly discontinued Fadogia in 2024 ("research has not progressed far enough"); Huberman did not proactively retract the endorsement. Tongkat Ali remains in Huberman's personal stack as of 2026.
2. Peter Attia silence. Despite extensive TRT content, Attia has not endorsed Tongkat Ali — an implicit skepticism signal his audience reads correctly.
3. Fadogia discontinuation without retraction. A governance red flag for the whole natural-T-booster niche.
4. Akarali SEO saturation. A majority of English-language "expert reviews" of Tongkat Ali online are Akarali's own commercial content. Treat as advertising, not independent review.
5. Momentous transparency gap. No published eurycomanone / eurypeptide % on Momentous Tongkat Ali product.
6. Anti-estrogen / aromatase-inhibitor claim debunked by community bloodwork: Bodybuilding.com TRT+TA stack N=1 showed E2 +45 % (not reduction).
7. FAERS "amazing results" on cheap products consistent with historical sildenafil/tadalafil adulteration pattern.
8. Wild-harvest sustainability: Malaysia exports banned, raw-root tree listed critically endangered under Act 686; Indonesian sources dominant but less regulated — buyer inherits the contamination risk.
9. Women using continuously without safety data — aggressive marketing to women post-2023 without pregnancy, lactation, PCOS, or hormone-sensitive-cancer safety data.

Folk vs Clinical Reality Check

The most robust anecdotal patterns — libido/morning-wood improvement, insomnia if dosed late, irritability in eugonadal young men — match biological plausibility and limited RCT signals. The "massive T increase" narrative is not supported by forum bloodwork: many N=1 reports show unchanged labs despite subjective improvement, and the only controlled bloodwork sequence the community has (Bodybuilding.com TRT stack) shows E2 rising alongside T, not the marketed "anti-estrogen" pattern. Tongkat Ali underdelivers what Huberman's audience expects of it and over-delivers the under-discussed insomnia/irritability side-effect profile. Food-first changes — sleep quantity, weight loss to BMI 22–26, resistance training, vitamin D sufficiency — produce larger testosterone shifts than TA 200 mg/day.

Deep Dive

Chemistry & Bioactives

Eurycoma longifolia Jack (family Simaroubaceae) contains >65 bioactive compounds. The root is the active part. Clinically relevant classes:

• Quassinoids (degraded triterpenes): eurycomanone (major, 0.8–2.0 % in standardized extracts), 13α(21)-epoxyeurycomanone, 13α,21-dihydroeurycomanone, eurycomanol, eurycolactone. MW 390–450 g/mol. Lipophilic; absorb with fat.
• β-carboline alkaloids: 9-methoxycanthin-6-one (cytotoxic), canthin-6-one (weak PDE-5 inhibition), 9-hydroxycanthin-6-one.
• Eurypeptides: small peptides with antioxidant and putative androgenic activity.
• Glycosaponins: adaptogenic fraction.

Pharmacokinetics

• Absorption: passive diffusion, small intestine; Tmax 2–4 h; food (fat) raises bioavailability ~30–40 %.
• Distribution: Vd 2–4 L/kg (rat, eurycomanone); high protein binding (60–80 % albumin). Limited BBB penetration for quassinoids; some alkaloid CNS penetration.
• Metabolism: hepatic CYP3A4 (major), CYP2C9, CYP2D6 (minor); Phase II glucuronidation and sulfation.
• Elimination: t½ 4–6 h (eurycomanone); fecal/biliary 60–70 %, urinary 30–40 %. Steady state in 2–3 days.
• Human PK: sparse. Ahmad 2018 (PMID 29997335) reported bioavailability ~25–35 % for eurycomanone in standardized water extract vs ~20 % for pure compound. 2024–2026 new analytical methods (PMID 40263641) but no new human PK — the bioavailability numbers in marketing are extrapolated from one 2018 study.

Mechanism

1. HPG-axis stimulation (primary): eurycomanone raises GnRH → LH/FSH → Leydig-cell testosterone biosynthesis without suppressing feedback. Aromatase inhibition is weak and the Bodybuilding forum E2 +45 % signal refutes clinically meaningful AI activity.
2. HPA-axis normalization: reduces elevated cortisol in chronically stressed individuals; doesn't blunt acute stress response.
3. Mild PDE-5 inhibition via canthin-6-one alkaloids.
4. Dopaminergic stimulation (PMID 39066784, 2025): eurycomanone increased dopamine release in SH-SY5Y cells, outperforming clorgyline at 15 μM — proposed CNS aphrodisiac mechanism.
5. AANAT / melatonin pathway (PMID 40395793, 2025, Japan): quassinoids upregulated AANAT in vitro — mechanistic support for sleep-architecture effects.
6. SRD5A1 upregulation via NF-κB / DNMT (PMID 41672378, 2026, China): eurycomanol restored cortisol metabolism in hyperuricemic mice, upregulated hepatic 5α-reductase — novel HPAandrogen-metabolism link.
7. Preclinical-only: anti-inflammatory (COX-2, NF-κB, TNF-α ↓), immunomodulation (CD4+/CD8+/NK↑), anti-EMT in NSCLC (PMID 40806251), anti-hyperuricemic lead (PMID 40790034 Nat Commun 2025), invertebrate longevity (PMID 41954810).

Clinical Trials Landscape (via BioMCP / ClinicalTrials.gov)

No Phase 3 registered globally. No large pivotal trial in the pipeline.

Regulatory Status

Ataraxia Verdict (as of 2026-04-17)

Hype Check

Tongkat Ali is the archetypal Huberman-era supplement: a real but modest herbal adaptogen repackaged by podcast economics into a "natural testosterone boost." The underlying Leisegang 2022 meta-analysis is genuine signal (SMD 1.35 in 5 RCTs N=343 hypogonadal men), but Morgado 2024 — the best recent SR — rates it only "possibly effective," and no society guideline has incorporated it. Forum bloodwork often doesn't replicate the T increase individual users expect based on podcasts. Subjective benefits (libido, morning wood, stress reduction) are real for a responder subset; the hard lab signal is narrower than the cultural signal.

Evidence Classification

Evidence Gaps

• No long-term (>12 months) human safety data.
• No pharmacogenomic / CYP response stratification.
• Thin female data: 2 RCTs, both Biotropics-sponsored; no PCOS, pregnancy, lactation, premenopausal cycle, or hormone-sensitive-cancer data.
• No head-to-head RCTs vs Ashwagandha, TRT, or placebo-controlled resistance training alone.
• No Cochrane review, no Phase 3 trial globally, no society guideline inclusion.
• Bioavailability numbers rest on a single 2018 PK study.

Bias Flags

• Industry concentration: the clinical literature is dominated by Biotropics (Physta, Malaysia) and HP Ingredients (LJ100, USA) — the two extract developers. Leisegang 2022 MA and Muniandy 2025 menopause RCT both industry-adjacent.
• Author SAB overlap: George/Henkel/Tambi reviews have Malaysian government / Biotropics funding ties.
• Selection/publication bias: small-N trials, industry-sponsored, with favorable effect sizes not replicated by independent groups.
• Akarali SEO: much English-language "review" content online is one commercial brand's marketing.

Manipulation Flags

• Huberman → Momentous commercial pipeline (2022–present). The single largest amplifier of demand.
• Fadogia quietly discontinued by Momentous 2024 without proactive podcast retraction — pattern for how the stack is promoted and depromoted.
• "Natural TRT alternative" framing — misleading. TA supports HPG recovery in hypogonadal men; it does not substitute for TRT.
• "Anti-estrogen / aromatase inhibitor" marketing — contradicted by actual community bloodwork.
• Wellness influencer affiliate economy (Rogan, Greenfield, Gillett, Hone Health, AstroFlav) amplifying a narrow RCT signal into a general men's health supplement.
• Counter-direction manipulation (cui bono on fearmongering): none detected. Pharma has no motive to fearmonger a cheap herbal. The only "fear" signals are the EFSA genotoxicity rejection (which is the EU scientific body, not a pharma competitor) and the LiverTox entry (NIH, same).

Decision Support

Clarity Compass verdict: CONDITIONAL.

• Health utility: 5/10. Strong-for-narrow (documented hypogonadism, chronic stress, menopausal QoL); weak-to-absent elsewhere. Effect sizes are moderate where real.
• Opportunity cost: $15–60/month for ~3-star indications; $30/mo for Physta or LJ100 is the reasonable tier. Attention cost low (one morning capsule). Requires biomarker tracking to confirm response.
• Hell-Yes-or-No test (Sivers): not a hell-yes. A reasonable "try for 8–12 weeks if criteria met, retest, decide." Skip if criteria not met.
• Regret minimization: in 5 years, would you regret not having TA documented and understood? Yes — it's culturally prominent and deserves an honest file. Would you regret not taking it? Only if you're in the responder subset and missed the trial; everyone else, no.

Who should try this (conditional yes):

• Men with two AM total T draws <12 nmol/L and ADAM symptoms — 8–12 wk Physta/LJ100 200 mg → 300 mg if no response at week 4.
• Adults with chronic psychological stress PSS 14–24 not meeting clinical anxiety criteria — 200 mg × 4 weeks.
• Perimenopausal women 40–55 with MENQOL-validated symptoms and no hormone-sensitive cancer history — 100 mg Physta × 12 wk.
• Responders should retest labs at 8–12 wk and stop if no change.

Who should skip:

• Men with baseline T >15 nmol/L hoping for muscle, libido, or cognitive boost — the evidence says <7 % change, indistinguishable from diurnal variation.
• Anyone expecting a cognitive/longevity/muscle-building effect — not supported.
• Users unwilling to buy Physta or LJ100 — the adulteration/contamination risk on random Amazon products is larger than the compound's pharmacological risk.
• Women pregnant, lactating, PCOS, or with hormone-sensitive-cancer risk.
• Athletes prioritizing cheap, proven ergogenic strategies (creatine, protein, sleep, training volume).

Bottom Line

A possibly-effective herbal adjunct for a narrow responder population, hyped into a general men's health staple by podcast economics. Evidence plateaued 2022; no Phase 3 registered; EFSA rejected as novel food citing genotoxicity; two published DILI cases. Food-first and lifestyle (sleep, weight loss, resistance training, vitamin D sufficiency) produce larger testosterone shifts than 200 mg/day. If you use it, buy Physta or LJ100 with batch-specific CoAs, dose in the morning, and retest labs at 8–12 weeks.

Practical Notes

Brands & Sourcing

• Clinically-evidenced extracts only: Physta (Biotropics Malaysia licensees) or LJ100 (HP Ingredients USA licensees). Anything else carries materially higher adulteration/contamination risk.
• Quality markers: batch-specific CoA showing eurycomanone %, heavy metals (Hg <0.2 ppm, Pb <5 ppm, As/Cd <0.5 ppm), microbial counts, DNA-confirmed identity.
• Third-party certifications: USP Verified, NSF Certified for Sport, Informed Choice, ConsumerLab.
• Notable brands: Nootropics Depot (Eurycomax), Transparent Labs LJ100, Biotropics direct (Malaysia), Pure Encapsulations, Momentous (Informed Sport tested but eurycomanone % not published).
• Avoid: generic "200:1 root extract" products, proprietary blends, products under $10/month, Amazon products without third-party testing, products marketed via affiliate coupon codes without CoA disclosure.

Storage

Room temperature (15–25 °C), opaque container, low humidity. Shelf life 2–3 years unopened, 18–24 months opened. Powders degrade faster than capsules above 30 °C.

Palatability

Raw powder is intensely bitter (quassinoid). Capsules avoid taste entirely and allow precise dosing — default form. Tinctures bitter with alcohol notes; limited clinical use.

Exercise & Circadian Alignment

Dose 7–9 AM with breakfast to align with endogenous testosterone peak. Do not use as acute pre-workout — no acute ergogenic effect; strength benefit requires 8–12 weeks of daily use plus concurrent training. Avoid dosing after 2 PM regardless of training schedule.

Reference Ranges (adult males for TA monitoring)

Cost

• Physta 200 mg/day: $25–40/month.
• LJ100 200 mg/day: $20–35/month.
• Generic standardized (verified third-party): $15–25/month — acceptable if CoA present.
• 12-week trial at 200 mg/day: $45–120 total.
• Comparison: TRT $50–200/month plus quarterly labs; more potent but suppresses endogenous HPG feedback.

What We Don't Know

1. Long-term (>12 months) human safety.
2. Female safety profile beyond 2 perimenopause RCTs (PCOS, pregnancy, lactation, premenopausal cycle effects, hormone-sensitive cancer interaction).
3. Pharmacogenomic response stratification (CYP3A4, SRD5A2, AR CAG, COMT).
4. Clinical relevance of EFSA 2021 genotoxicity signal at therapeutic (not 200× therapeutic) exposure — no published follow-up.
5. Mechanism of rare DILI cases — idiosyncratic, dose-dependent, or product-dependent.
6. Head-to-head vs Ashwagandha, TRT, or resistance training alone for T elevation and stress reduction.
7. Dose–response curve — is 100 mg ≈ 200 mg ≈ 400 mg, or is there a true gradient?
8. Effect of extraction method variability (water vs ethanolic vs quassinoid-rich fractions) on clinical outcome.
9. Whether the DLBS5055 Phase 4 male-infertility trial (NCT06100432, 2025–2026 readout) will confirm or deflate existing fertility claims.
10. True prevalence of heavy-metal contamination in the 2024–2026 Indonesian-dominant supply chain (Ang's Malaysian data is 20 years old).

References

Meta-Analyses & Systematic Reviews

• Leisegang K et al. 2022. Medicina 58(8):1047. PMID 36013514 — 5-RCT MA (N=343) hypogonadal T increase, SMD 1.35 (95 % CI 0.57–2.14).
• Kotirum S et al. 2015. Complement Ther Med 23(5):693. PMID 26365449 — ED MA (4 RCTs), IIEF-5 SMD 0.36; heterogeneity I²=89.5 %.
• Morgado A et al. 2024. Int J Impot Res. PMID 37697053 — Testosterone boosters SR; TA rated "possibly effective" (second-weakest tier).
• Thu HE et al. 2017. Chin J Nat Med 15(1):71. PMID 28259255 — SR male sexual health.
• Santos HO et al. 2019. J Ethnopharmacol 235:392. PMID 30790614 — Phytotherapics beyond Tribulus.
• Kuchakulla M et al. 2021. SR of popular T-booster ingredients. PMID 32358510.
• Ulbricht C et al. 2013. J Diet Suppl 10(1):54. PMID 23419023 — Natural Standard evidence review.
• Rehman SU et al. 2016. Molecules 21(3):331. PMID 26978330 — Traditional use + chemistry review.
• Sukardiman et al. 2025. SR Indonesian ED plants. PMID 40007786.

Key RCTs

• Talbott SM et al. 2013. J Int Soc Sports Nutr 10(1):28. PMID 23705671 — Stress hormones (N=63).
• Chinnappan SM et al. 2021. Food Nutr Res 65. PMID 34262417 — Physta 200 mg aging men (N=105).
• Leitão AE et al. 2021a. Maturitas 145:78. PMID 33541567 — 6-mo ADAM + exercise (N=45).
• Leitão AE et al. 2021b. Complement Ther Clin Pract 42:101301. PMID 33445146 — Strength + cardio in androgen-deficient men.
• Chen CK et al. 2019. Int J Prev Med 10:118. PMID 31367282 — 300 mg + resistance training (N=32).
• Henkel RR et al. 2014. Phytother Res 28(4):544. PMID 23754792 — Pilot seniors (N=25).
• Tambi MI et al. 2012. Andrologia 44 Suppl 1:226. PMID 21671978 — Late-onset hypogonadism (N=76).
• Muniandy K et al. 2025. World J Clin Cases. PMID 41283187 — Physta perimenopause RCT (N=138), MENQOL −33.9 %, hormonal neutrality. New.
• George A et al. 2016. Phytother Res 30(4):627. PMID 26816234 — Physta immunomodulation (N=83).

Mechanism (2024–2026)

• Ang SY et al. 2025. Nat Prod Res. PMID 39066784 — Dopaminergic stimulation SH-SY5Y.
• Han K et al. 2025. RSC Adv. PMID 40395793 — AANAT melatonin biosynthesis upregulation.
• Pan X et al. 2026. Biochem Pharmacol. PMID 41672378 — Eurycomanol SRD5A1 / cortisol metabolism.
• Sakai N et al. 2024. Sleep Adv 5(1):zpae047. PMID 39055967 — Wake/NREM consolidation mice.
• Ono N et al. 2023. Eur J Neurosci. PMID 37968729 — Wakefulness active / sleep resting mice.
• Soddaen P et al. 2025. Eurycomanone TGF-β/Smad EMT NSCLC. PMID 40806251.
• Zhang Y et al. 2025. Nat Commun. PMID 40790034 — β-carboline 32 anti-hyperuricemic lead.
• Liu H et al. 2026. Biogerontology. PMID 41954810 — ELP invertebrate longevity.
• Eissa MA, Farag MA. 2025. J Ethnopharmacol. PMID 39369924 — Metabolome variability + 5-FU testicular protection rat.

Safety

• EFSA NDA Panel. 2021. EFSA J 19(12):6937. PMID 34987621 — Novel food REJECTED; genotoxicity signal.
• LiverTox. 2024. Tongkat Ali. NBK609015. Also catalog entry PMID 39527684.
• Kaliounji A et al. 2024. Cureus. PMID 38646387 — First published DILI case.
• Ali A et al. 2025. Cureus. PMID 41080360 — Atrial flutter case 71 y/o male.
• Ang HH, Lee KL. 2004. Int J Toxicol. PMID 15162849 — Mercury 36 % Malaysian products.
• Ang HH et al. 2006. Food Chem Toxicol. PMID 16567029 — Tongkat Ali Hitam mercury.
• Said M et al. 2014. Food Chem. PMID 24731345 — Sildenafil adulteration NIR.
• Abubakar BM et al. 2018. Pharm Biol. PMID 30058427 — DNA barcoding adulteration.
• Salman SA et al. 2010. J Clin Pharm Ther. PMID 21054461 — Propranolol interaction.
• Han YM et al. 2015. Evid Based Complement Alternat Med. PMID 26240600 — CYP3A4 in vitro.

Pharmacokinetics

• Ahmad N et al. 2018. Pharmaceutics 10(3):90. PMID 29997335 — Eurycomanone bioavailability standardized water extract.
• Low BS et al. 2005. Planta Med 71(9):803. PMID 16206032 — First PK.
• Farag MA et al. 2022. ACS Omega 8(2):1838. PMID 36687023 — Bioactives/analytics review.
• Alqahtani A et al. 2025. Fluorescent quantification eurycomanone. PMID 40263641.

Regulatory / Guidelines / Traditional

• Panossian A, Lemerond T. 2025. Pharmaceuticals. PMID 41011217 — Adaptogen framing (industry-adjacent).
• Ye L et al. 2024. Zhongguo Zhong Yao Za Zhi. PMID 39701690 — Chinese TCM positioning.
• George A, Henkel R. 2014. Andrologia 46(7):708. PMID 24386995 — Phytoandrogenic review (industry-adjacent).
• Wahab NA et al. 2022. Online information quality audit. PMID 36231154.

Pipeline

• NCT06100432 — DLBS5055 Phase 4 male infertility (Indonesia, N=90, completion 2025-10).
• Malaysian Standard MS2409 — Tongkat Ali quality standard.